Cargando…

Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials

The safety and usefulness of pioglitazone (Pio) is repeatedly called into question due to the contradictory information available about it. A meta-analysis and risk benefit assessment was conducted to address the various points of debate regarding Pio. Electronic database search (Cochrane library, E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinha, Binayak, Ghosal, Samit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519682/ https://www.ncbi.nlm.nih.gov/pubmed/32978507 http://dx.doi.org/10.1038/s41598-020-72967-8

Ejemplares similares

Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring
por: Ghosal, Samit, et al.
Publicado: (2023)

Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis
por: Ghosal, Samit, et al.
Publicado: (2022)

Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
por: Ghosal, Samit, et al.
Publicado: (2023)

A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials
por: Sinha, Binayak, et al.
Publicado: (2021)

Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
por: Sinha, Binayak, et al.
Publicado: (2020)

A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
por: Ghosal, Samit, et al.
Publicado: (2021)

Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
por: Ghosal, Samit, et al.
Publicado: (2023)

A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
por: Sinha, Binayak, et al.
Publicado: (2022)

Quantitative measure of asymptomatic cardiovascular disease risk in Type 2 diabetes: Evidence from Indian outpatient setting
por: Ghosal, Samit, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
por: Sinha, Binayak, et al.
Publicado: (2019)

LBODP046 Reduction In "Cardiovascular Death Or Hospitalisation For Heart Failure" With Sglt-2is Is Dependent On Weight Reduction: A Meta-regression Analysis
por: Ghosal, Samit, et al.
Publicado: (2022)

Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS
por: Ghosal, Samit, et al.
Publicado: (2016)

Rapid sputum testing and not thermal screening alone should be the first-line screening test at airports: A Bayesian analysis
por: Ghosal, Samit, et al.
Publicado: (2020)

Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysis
por: Ghosal, Samit, et al.
Publicado: (2020)

Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis
por: Ghosal, Samit, et al.
Publicado: (2020)

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
por: Sinha, Binayak, et al.
Publicado: (2014)

“Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors – A survey"
por: Gangopadhyay, Kalyan Kumar, et al.
Publicado: (2020)

The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials
por: Ghosal, Samit, et al.
Publicado: (2023)

Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020)
por: Ghosal, Samit, et al.
Publicado: (2020)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Derosa, Giuseppe, et al.
Publicado: (2009)

Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice
por: Iizuka, Yuzuru, et al.
Publicado: (2018)

Pioglitazone and thyroid cancer risk in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2014)

Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India
por: Wangnoo, Subhash Kumar, et al.
Publicado: (2016)

Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
por: Lian, Jingxuan, et al.
Publicado: (2021)

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis
por: Wang, Ben, et al.
Publicado: (2018)

Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone
por: Tseng, Chin-Hsiao
Publicado: (2019)

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone
por: Agrawal, Prabhat, et al.
Publicado: (2021)

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
por: Satirapoj, Bancha, et al.
Publicado: (2018)

Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis
por: Clar, Christine, et al.
Publicado: (2009)

Corrigendum: Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
por: Lian, Jingxuan, et al.
Publicado: (2022)

Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
por: Yamanouchi, Toshikazu
Publicado: (2010)

Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
por: Desouza, Cyrus V., et al.
Publicado: (2010)

Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
por: Alam, Fahmida, et al.
Publicado: (2019)

Reply to letter to the editor regarding article: Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis (Ghosal et al.)
por: Ghosal, Samit
Publicado: (2020)

Sodium‐glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta‐analysis of randomized controlled trials
por: Liao, Hung‐Wei, et al.
Publicado: (2018)

Treat-to-target trials in diabetes
por: Wangnoo, Subhash K., et al.
Publicado: (2014)

Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
por: Filipova, Elena, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0mv5n3ddqcsbka17s3v93h6nnn